Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.49 |
| ▸ | MET | P08581 | 9/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | FES | P07332 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | FER | P16591 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.41 |
| ▸ | CSK | P41240 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24885851 | 1.00 | ROCK2 (0.49) | ROCK2METCYP3A4MAP3K7MAP4K2 | |
| SCHEMBL19986860 | 0.86 | MET (0.49) | ROCK2METMAP3K7MAP4K2MAPK14 | |
| SCHEMBL31061568 | 0.81 | MAP3K7 (0.53) | ROCK2METMAP3K7MAP4K2MAPK14 | |
| SCHEMBL31554522 | 0.81 | ROCK2 (0.65) | ROCK2METCYP3A4 | |
| SCHEMBL3485162 | 0.81 | ROCK2 (0.52) | ROCK2METCYP3A4 | |
| SCHEMBL2879737 | 0.81 | ROCK2 (0.65) | ROCK2METCYP3A4 | |
| Hydrochloric Acid SCHEMBL5097103 | 0.80 | ROCK2 (0.64) | ROCK2METCYP3A4 | |
| SCHEMBL1896008 | 0.79 | TTBK1 (0.56) | ROCK2METMAPK14KDR | |
| SCHEMBL29837329 | 0.78 | ROCK2 (0.53) | ROCK2METCYP3A4MAPK14FLT3 | |
| SCHEMBL25793147 | 0.78 | ROCK2 (0.53) | ROCK2METCYP3A4MAPK14FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | ROCK2 417/4885MET 709/4885CYP3A4 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.